Clinical Trial Update: A Study of MM-111 in Patients With Advanced, Refractory Her2 Amplified, Heregulin Positive Cancers [Phase 1]

View source ↗

Summary

Phase 1 study of MM-111 in advanced, refractory HER2-amplified, heregulin-positive cancers has completed and results were posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Solid Tumors

Drugs mentioned

• MM-111

Snippet

Sponsor: Merrimack Pharmaceuticals | Conditions: Her2 Amplified Solid Tumors, Metastatic Breast Cancer | Phase 1 | Status: COMPLETED | Results posted: 2014-09-15